150 related articles for article (PubMed ID: 34766555)
21. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
22. In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma.
Hernandez A; Muñoz-Mármol AM; Esteve-Codina A; Alameda F; Carrato C; Pineda E; Arpí-Lluciá O; Martinez-García M; Mallo M; Gut M; Del Barco S; Gallego O; Dabad M; Mesia C; Bellosillo B; Domenech M; Vidal N; Aldecoa I; de la Iglesia N; Balana C
Sci Rep; 2022 Aug; 12(1):14439. PubMed ID: 36002559
[TBL] [Abstract][Full Text] [Related]
23. Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases.
Ballester LY; Moghadamtousi SZ; Leeds NE; Huse JT; Fuller GN
Acta Neuropathol Commun; 2019 Apr; 7(1):63. PubMed ID: 31036092
[No Abstract] [Full Text] [Related]
24. Can adult
Gilani A; Davies KD; Kleinschmidt-DeMasters BK
Clin Neuropathol; 2021; 40(3):165-167. PubMed ID: 33769273
[No Abstract] [Full Text] [Related]
25. Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions.
Chen HM; Yu K; Tang XY; Bao ZS; Jiang T; Fan XL; Chen XW; Su XD
FEBS Lett; 2015 Jun; 589(13):1437-43. PubMed ID: 25935522
[TBL] [Abstract][Full Text] [Related]
26. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
[No Abstract] [Full Text] [Related]
27. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
[TBL] [Abstract][Full Text] [Related]
28. Multiple functions of a glioblastoma fusion oncogene.
Babic I; Mischel PS
J Clin Invest; 2013 Feb; 123(2):548-51. PubMed ID: 23298839
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
[TBL] [Abstract][Full Text] [Related]
30. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
International Cancer Genome Consortium PedBrain Tumor Project
Nat Med; 2016 Nov; 22(11):1314-1320. PubMed ID: 27748748
[TBL] [Abstract][Full Text] [Related]
31. FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
[TBL] [Abstract][Full Text] [Related]
32. Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.
Di Stefano AL; Picca A; Saragoussi E; Bielle F; Ducray F; Villa C; Eoli M; Paterra R; Bellu L; Mathon B; Capelle L; Bourg V; Gloaguen A; Philippe C; Frouin V; Schmitt Y; Lerond J; Leclerc J; Lasorella A; Iavarone A; Mokhtari K; Savatovsky J; Alentorn A; Sanson M;
Neuro Oncol; 2020 Nov; 22(11):1614-1624. PubMed ID: 32413119
[TBL] [Abstract][Full Text] [Related]
33. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.
Picca A; Sansone G; Santonocito OS; Mazzanti CM; Sanson M; Di Stefano AL
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067258
[TBL] [Abstract][Full Text] [Related]
34. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.
Nakano Y; Tomiyama A; Kohno T; Yoshida A; Yamasaki K; Ozawa T; Fukuoka K; Fukushima H; Inoue T; Hara J; Sakamoto H; Ichimura K
Brain Tumor Pathol; 2019 Jan; 36(1):14-19. PubMed ID: 30350109
[TBL] [Abstract][Full Text] [Related]
35. IDH-mutant gliomas with additional class-defining molecular events.
Ahrendsen JT; Torre M; Meredith DM; Hornick JL; Reardon DA; Wen PY; Yeo KK; Malinowski S; Ligon KL; Ramkissoon S; Alexandrescu S
Mod Pathol; 2021 Jul; 34(7):1236-1244. PubMed ID: 33772213
[TBL] [Abstract][Full Text] [Related]
36. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
37. Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.
Wefers AK; Stichel D; Schrimpf D; Coras R; Pages M; Tauziède-Espariat A; Varlet P; Schwarz D; Söylemezoglu F; Pohl U; Pimentel J; Meyer J; Hewer E; Japp A; Joshi A; Reuss DE; Reinhardt A; Sievers P; Casalini MB; Ebrahimi A; Huang K; Koelsche C; Low HL; Rebelo O; Marnoto D; Becker AJ; Staszewski O; Mittelbronn M; Hasselblatt M; Schittenhelm J; Cheesman E; de Oliveira RS; Queiroz RGP; Valera ET; Hans VH; Korshunov A; Olar A; Ligon KL; Pfister SM; Jaunmuktane Z; Brandner S; Tatevossian RG; Ellison DW; Jacques TS; Honavar M; Aronica E; Thom M; Sahm F; von Deimling A; Jones DTW; Blumcke I; Capper D
Acta Neuropathol; 2020 Jan; 139(1):193-209. PubMed ID: 31563982
[TBL] [Abstract][Full Text] [Related]
38. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Davare MA; Henderson JJ; Agarwal A; Wagner JP; Iyer SR; Shah N; Woltjer R; Somwar R; Gilheeney SW; DeCarvalo A; Mikkelson T; Van Meir EG; Ladanyi M; Druker BJ
Clin Cancer Res; 2018 Dec; 24(24):6471-6482. PubMed ID: 30171048
[TBL] [Abstract][Full Text] [Related]
39. NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma.
Wang Y; Long P; Wang Y; Ma W
Front Oncol; 2020; 10():593578. PubMed ID: 33330081
[TBL] [Abstract][Full Text] [Related]
40. FGFR-TACC gene fusions in human glioma.
Lasorella A; Sanson M; Iavarone A
Neuro Oncol; 2017 Apr; 19(4):475-483. PubMed ID: 27852792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]